Oxford Biomedica plc

LSE:OXB Stock Report

Market Cap: UK£758.2m

Oxford Biomedica Future Growth

Future criteria checks 5/6

Oxford Biomedica is forecast to grow earnings and revenue by 74.1% and 19% per annum respectively. EPS is expected to grow by 97.3% per annum. Return on equity is forecast to be 47.1% in 3 years.

Key information

74.1%

Earnings growth rate

97.28%

EPS growth rate

Biotechs earnings growth19.9%
Revenue growth rate19.0%
Future return on equity47.08%
Analyst coverage

Good

Last updated11 May 2026

Recent future growth updates

Recent updates

Narrative Update • May 20

OXB: Future Upside Will Depend On Fast Track Execution Success

Analysts have adjusted their price target on Oxford Biomedica to reflect updated assumptions on discount rate, revenue growth, profit margins and future P/E. The latest Street research has resumed coverage with a supportive stance on the stock and its long term value potential around £8.43.
Narrative Update • May 03

OXB: Future Cash Generation And Execution Risks Will Shape Balanced Outlook

Analysts have lifted their price target on Oxford Biomedica to £5.50, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that support a more refined view of the stock’s risk and earnings profile. Analyst Commentary Recent research coverage frames Oxford Biomedica as an opportunity with a refreshed risk and earnings profile, but not all commentary is uniformly positive.
Narrative Update • Apr 19

OXB: Future Performance Will Reflect Fast Track Platform Execution Success

Analysts have lifted their price target for Oxford Biomedica from £6.67 to £8.43, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that align with recent Street research support. Analyst Commentary Bullish Takeaways Bullish analysts see the resumed coverage as a sign that Oxford Biomedica is now better aligned with current sector assumptions on revenue growth and profitability, which feeds directly into the higher fair value estimate.
Narrative Update • Apr 04

OXB: Post Transition Buy Ratings Will Support Higher Quality Business Perception

Analysts have increased the updated fair value estimate for Oxford Biomedica from £9.50 to £11.70 per share, citing recent Buy ratings and higher price targets that reflect expectations for a higher quality business following the company’s transition. Analyst Commentary Recent research indicates that bullish analysts are becoming more constructive on Oxford Biomedica, with fresh Buy ratings and higher price objectives supporting the updated fair value estimate.
Narrative Update • Mar 21

OXB: Upgraded Rating Will Likely Expose Transition Risks In Execution

Analysts have raised their price target for Oxford Biomedica to £7.35 from £3.80. They cite the company's transition to what they view as a higher quality business as a key driver for the change.
Narrative Update • Mar 06

OXB: Higher Rating Will Likely Magnify Execution And Funding Risks

Analysts have lifted their price target on Oxford Biomedica from £3.80 to £7.35, citing a higher quality business profile following the company's transition and reflecting this in updated fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary The latest research points to a clearer view of Oxford Biomedica's equity story, with a higher price target of 735 GBp set alongside the view that the business profile has improved following its transition.
Narrative Update • Feb 20

OXB: Transition Progress And Buy Rating Will Support Higher Perceived Business Quality

Analysts have modestly trimmed their fair value estimate for Oxford Biomedica from £9.70 to £9.50, citing updated assumptions on discount rates, margins and future P/E. Some now see a higher quality business that supports a Buy rating and a higher £7.35 price target on the shares.
Narrative Update • Feb 06

OXB: Upgraded Rating Will Likely Expose Vulnerable Execution Assumptions

Analysts have lifted their price target on Oxford Biomedica to £7.35 from £3.80, citing a higher quality business following the company's transition and reflecting modest tweaks to the discount rate, revenue growth and profit margin assumptions, along with a slightly lower future P/E multiple. Analyst Commentary Recent research points to a business that analysts view as higher quality following Oxford Biomedica's transition, with the new £7.35 price target reflecting updated assumptions on discount rate, revenue and margin profiles, and a revised future P/E multiple.
Narrative Update • Jan 23

OXB: Upgraded Outlook Will Likely Expose Fragile Profitability Assumptions

Analysts have lifted their price target on Oxford Biomedica to £7.35 from £3.80, citing a higher quality business mix after the company’s transition and updated assumptions around revenue growth, profit margins and future P/E. Analyst Commentary Recent research highlights a shift in how the market is framing Oxford Biomedica.
Narrative Update • Jan 09

OXB: Transition Progress Will Drive Rerated Business Quality And Higher Confidence

Analysts lifted their price target on Oxford Biomedica to £7.35 from £3.80 after updating their fair value estimate and assumptions on the discount rate, revenue growth, profit margin and future P/E, reflecting increased confidence in the company’s transition and business quality. Analyst Commentary Recent research shows a clear shift in sentiment toward Oxford Biomedica, with bullish analysts pointing to a higher-quality business profile following the company’s transition.
Analysis Article • Dec 30

Revenues Working Against Oxford Biomedica plc's (LON:OXB) Share Price

With a price-to-sales (or "P/S") ratio of 4.9x Oxford Biomedica plc ( LON:OXB ) may be sending bullish signals at the...
Narrative Update • Dec 25

OXB: Higher Price Outlook Will Likely Expose Execution And Margin Weakness

Analysts have raised their price target on Oxford Biomedica to 970 GBp from 930 GBp, reflecting improved growth expectations despite a slightly higher discount rate and modestly lower projected profit margins. Analyst Commentary While the latest target price increase signals confidence in Oxford Biomedica's long term prospects, some Bearish analysts continue to flag risks around execution, profitability, and valuation.
Narrative Update • Dec 11

OXB: Future Performance Will Reflect US Capacity Expansion And Margin Execution Risks

Analysts have raised their price target on Oxford Biomedica to 970 GBp from 930 GBp, reflecting slightly stronger expectations for long term revenue growth and profit margins, while maintaining a broadly similar valuation multiple outlook. Analyst Commentary Analysts describe the higher price target as a reflection of improving confidence in Oxford Biomedica's ability to scale its revenue base and gradually enhance operating leverage, while still acknowledging execution risks in a competitive cell and gene therapy landscape.
Narrative Update • Nov 27

OXB: Future Performance Will Balance Revenue Momentum With Margin Execution Risks

Narrative Update on Oxford Biomedica Analysts have raised their price target for Oxford Biomedica by £0.55 to £6.48. This change reflects improved profit margin expectations and is reinforced by recent optimistic research updates.
Narrative Update • Sep 13

CDMO Expansion Will Widen Global Cell And Gene Therapy Access

Analysts have raised Oxford Biomedica’s price target from £5.55 to £5.93, citing improved growth prospects, commercial execution, and operational strength, with ongoing share price weakness seen as a potential entry point despite lingering market uncertainties and execution risks. Analyst Commentary Bullish analysts cite an improved growth outlook and enhanced commercial execution as key drivers for the upward price target revision.
Analysis Article • Sep 12

Investors Still Aren't Entirely Convinced By Oxford Biomedica plc's (LON:OXB) Revenues Despite 35% Price Jump

Oxford Biomedica plc ( LON:OXB ) shares have continued their recent momentum with a 35% gain in the last month alone...
Narrative Update • Aug 27

CDMO Expansion Will Widen Global Cell And Gene Therapy Access

Analysts have raised Oxford Biomedica’s price target from £5.08 to £5.40, citing strong commercial execution and improving fundamentals despite some concerns over market visibility and client demand. Analyst Commentary Bullish analysts highlight Oxford Biomedica’s strong commercial track record and operational excellence as underpinning their positive outlook.
Analysis Article • Jul 29

Oxford Biomedica plc's (LON:OXB) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Despite an already strong run, Oxford Biomedica plc ( LON:OXB ) shares have been powering on, with a gain of 30% in the...
User avatar
New Narrative • May 09

CDMO Expansion Will Widen Global Cell And Gene Therapy Access

Expansion into AAV and other vector types reduces dependency risks and supports earnings growth through diversified revenue streams.
Analysis Article • Apr 10

Health Check: How Prudently Does Oxford Biomedica (LON:OXB) Use Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Feb 28

Oxford Biomedica plc (LON:OXB) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

The Oxford Biomedica plc ( LON:OXB ) share price has fared very poorly over the last month, falling by a substantial...
Analysis Article • Oct 19

Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Aug 23

Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%

The Oxford Biomedica plc ( LON:OXB ) share price has fared very poorly over the last month, falling by a substantial...

Earnings and Revenue Growth Forecasts

LSE:OXB - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20283395052806
12/31/20272891916417
12/31/2026229-9-19137
12/31/2025169-30-41N/A
9/30/2025160-34-8-4N/A
6/30/2025151-37-12-8N/A
3/31/2025140-40-35-29N/A
12/31/2024129-43-58-51N/A
9/30/2024113-93-65-56N/A
6/30/202497-142-72-62N/A
3/31/202493-150-55-45N/A
12/31/202390-157-38-29N/A
9/30/2023104-110-24-11N/A
6/30/2023119-62-96N/A
3/31/2023130-50-19-3N/A
12/31/2022140-39-29-13N/A
9/30/2022133-32-31-17N/A
6/30/2022126-25-33-21N/A
3/31/2022134-3-92N/A
12/31/2021143191625N/A
9/30/2021139191526N/A
6/30/2021135191526N/A
3/31/20211116215N/A
12/31/202088-6-103N/A
9/30/202077-9-16-1N/A
6/30/202066-13-22-6N/A
3/31/202065-14-26-5N/A
12/31/201964-16-29-4N/A
9/30/201964-12N/A-4N/A
6/30/201964-8N/A-4N/A
3/31/2019650N/A4N/A
12/31/2018678N/A13N/A
9/30/2018624N/A18N/A
6/30/2018570N/A23N/A
3/31/201847-5N/A13N/A
12/31/201738-9N/A3N/A
9/30/201734-10N/A-1N/A
6/30/201731-11N/A-6N/A
3/31/201729-14N/A-4N/A
12/31/201628-17N/A-2N/A
9/30/201626-16N/A-1N/A
6/30/201624-16N/A-1N/A
3/31/201620-15N/A-7N/A
12/31/201516-13N/A-13N/A
9/30/201515-12N/A-12N/A
6/30/201513-10N/A-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OXB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.4%).

Earnings vs Market: OXB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: OXB is expected to become profitable in the next 3 years.

Revenue vs Market: OXB's revenue (19% per year) is forecast to grow faster than the UK market (4.5% per year).

High Growth Revenue: OXB's revenue (19% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: OXB's Return on Equity is forecast to be very high in 3 years time (47.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/28 11:51
End of Day Share Price 2026/05/28 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oxford Biomedica plc is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kane SlutzkinDeutsche Bank
Susie JanaEdison Investment Research
Jens LindqvistInvestec Bank plc (UK)